Electrotransfer of human IL‐1Ra into skeletal muscles reduces the incidence of murine collagen‐induced arthritis

Jeong, Jae-Gyun; Kim, Jong-Mook; Ho, Seong-Hyun; Hahn, Woong; Yu, Seung Shin; Kim, Sun‐Young

doi:10.1002/jgm.599

Cited by 28 publications

(7 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The transfection efficiency by electroporation is many times greater than that of naked DNA injection, with markedly reduced inter‐individual variability 5, 6. Gene transfer by electroporation in vivo has been effective for introducing DNA into rat hepatocellular carcinomas, hepatocytes, mouse testes, melanoma, skeletal muscle, skin, lung and rat skeletal muscle for correcting anemia of renal failure 7–13. Particularly, skeletal muscle has been shown to be the most promising tissue for electro‐gene transfer in several contexts: (i) There is no significant cell replacement in skeletal muscle tissue, so that introduced genes are not rapidly lost following mitosis 14; transgene expression can persist for relatively long periods 15; and (ii) Skeletal muscle has an abundant blood vascular supply, thus providing an efficient transport system for the carriage of secreted protein into the circulation.…”

Section: Introductionmentioning

confidence: 99%

Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved

Feng¹,

Heston²,

Shollenberger³

et al. 2005

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved

Feng¹,

Heston²,

Shollenberger³

et al. 2005

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…An examination of various electric field strengths and doses of plasmid DNA, using IL-1Ra as the transgene suggested that dose and electric field can be optimized for peak expression and maintenance [92]. The study examining i.m.…”

Section: Electrotransfermentioning

confidence: 98%

“…Elevated and sustained plasma levels of the protein product have been achieved after intramuscular electrotransfer of naked DNA [88][89][90]. The use of electrotransfer to enhance gene therapy as applied to various animal models of arthritis has received considerable attention over the past five years (Table 6) [10,18,91,92,66,93,64,75,63]. …”

Section: Electrotransfermentioning

confidence: 99%

Gene Therapy for Rheumatoid Arthritis: Recent Advances

Woods¹,

Sitabkhan²,

Koch³

2008

CGT

View full text Add to dashboard Cite

The treatment of rheumatoid arthritis (RA) in the last decade has made enormous advances with the use of biological therapies. However, these therapies have serious limitations such as the expense, side-effects, and the requirement for repeated injections, each of which can potentially be obviated by gene therapy. A gene therapy approach for the treatment of RA has the potential to stably deliver a gene product or multiple products in a target-specific, disease-inducible manner. There are many studies investigating gene therapy in RA, the majority of which have been designed to test proof-of-principle in an animal model. With an abundance of animal studies that have established much promise, the field is now at the early stage of moving towards human trials, where patient benefit needs to overshadow associated risks, especially since RA is publicly perceived as a non-life-threatening disease. Here, we provide an overview that focuses on advances in the application of gene therapy to RA over the last five years, including: novel targets and approaches; the viral and non-viral applications most likely to succeed in the clinic; advances in our understanding of the contralateral effect; the latest successes with anti-inflammatory cytokines; and a review of advancements towards clinical trials.

show abstract

“…After injection of plasmid DNA in a tissue, appropriate local electric pulses can result in a very high expression of the transferred genes, 100 to 1000 fold compared to plasmid injection only [27]. Electroporation has been used very successfully to deliver therapeutic genes that encode for a variety of hormones, cytokines, enzymes in a variety of mammalian species: mice [18,28,29], rats [30,31], dogs [32], pigs [7] and cattle [33]. Additionally, plasmid injection and electroporation have been used successfully for vaccination purposes in ruminants [34,35].…”

Section: Target Tissue -Skeletal Musclementioning

confidence: 99%

Plasmid-Based Expression Technology Using Growth Hormone Releasing Hormone: A Novel Method for Physiologically Stimulating Long-Term Growth Hormone Secretion

Draghia-Akli¹,

Pope²,

Brown³

et al. 2006

CCHTS

View full text Add to dashboard Cite

Novel DNA-based technologies were recently introduced for various purposes, such as screening of targets identified from genomic projects, shuffled molecules for vaccination, or to direct the in vivo production of hormones and other peptides for therapeutic or preventative applications. We have used a plasmid-based technology to deliver growth hormone releasing hormone (GHRH) to various animal species for screening, toxicology and therapy. A single intramuscular injection of a low dose of plasmid followed by electroporation can ensure that the target species will produce physiological levels of GHRH for extended periods of time, which would replace costly, frequent injections of the recombinant hormone and improve the quality of life and compliance of patients. This therapeutic modality is of particular importance in circumstances requiring long-term administration of small molecules with naturally short half-life (e.g. treatment of anemia and cachexia associated with renal failure, cancer or other chronic disability). A similar technique was used to create, test and validate protease-resistant analogs of GHRH with significantly longer half-life. Analysis of the characteristics of each of the plasmid components and tissue-specific transcription factors and the choice of target tissue is imperative when designing plasmids for therapeutic applications. Using the species-specific sequences of GHRH or other molecule along with the appropriate choice of plasmid backbone and expression cassette components can result in long and steady expression of the transgene product.

show abstract

Electrotransfer of human IL‐1Ra into skeletal muscles reduces the incidence of murine collagen‐induced arthritis

Abstract: These results demonstrate that direct electrotransfer of plasmid containing the human IL-1Ra cDNA sequence to skeletal muscle can reduce the incidence of CIA in mice.

Cited by 28 publications

References 52 publications

Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved

Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved

Gene Therapy for Rheumatoid Arthritis: Recent Advances

Plasmid-Based Expression Technology Using Growth Hormone Releasing Hormone: A Novel Method for Physiologically Stimulating Long-Term Growth Hormone Secretion

Contact Info

Product

Resources

About